BiolineRx buys UK co Agalimmune

Philip Serlin  photo: PR
Philip Serlin photo: PR

BiolineRx is paying $6 million upfront for Agalimmune, which has developed a new immunotherapy solution for treating cancer.

BiolineRx Ltd. (Nasdaq: BLRX); TASE:BLRX) has announced the acquisition of Agalimmune Ltd., a private UK-based company with an innovative, anti-cancer immunotherapy platform. BiolineRx is paying $6 million upfront, of which $3 million is in cash and the remainder in BioLineRx shares. Additional future payments may be made based on development and commercial milestones.

This is the first significant move by new BiolineRx CEO Philip Serlin, who replaced Dr. Kinneret Savitsky in the post six months ago.

Agalimmune has developed a new immunotherapy solution for treating cancer. It says that its treatment not only kills the tumor cells at the site of injection, but also brings about a durable, follow-on, anti-metastatic immune response. The treatment has passed stag of trials on animals, and is expected to commence a first-in-man study in patients with solid tumors in the first half of 2018.

At the end of 2016, BiolineRx had $36 million cash. Its market cap is $64 million. It reported today that is made a net loss of $15.8 million in 2016, which compares with a loss of $14.4 million in 2015. The company reported no revenue in either year. R&D expenditure was $11.2 million in 2016, compared with $11.5 million in 2015.

BiolineRx has also announced that it has halted development of its product for treating celiac, which was about to enter a Phase II clinical trial. This means that the two leading products in its pipeline will be cancer therapies, specifically in the area of immunotherapy. Its remaining products are in the pre-clinical trials stage, most of them part of a collaboration with Novartis.

"Immuno-oncology is one of the most promising approaches for the treatment of cancer," Serlin said, "Although a number of current immunotherapies are receiving widespread attention, many solid tumors are still able to evade the immune system's surveillance. Most immunotherapies work best in highly mutated tumors that are infiltrated with immune cells, known as 'hot' tumors. Unfortunately, the overwhelming majority of tumors are 'cold' tumors, and thus transforming a 'cold' tumor into a 'hot' tumor is a major objective in cancer treatment.

"In this regard, Agalimmune's lead asset, AGI-134, harnesses naturally occurring, pre-existing antibodies to elicit a tumor-specific immune response that is unique to the treated individual and provides a universal, small-molecule approach to personalized immunotherapy. We are enthusiastic to incorporate into our pipeline this promising near-clinical asset, which substantially strengthens our position in the immuno-oncology space." "We are very excited that we found an ideal partner for our promising therapeutic pipeline. We are extremely impressed by BioLineRx's proven drug development capabilities, as well as their meaningful collaborations with global pharmaceutical companies," said Damian Marron, CEO of Agalimmune.

The main shareholders in BiolineRx are Novartis and Senvest Management LLC.

Published by Globes [online], Israel business news - www.globes-online.com - on March 23, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

Philip Serlin  photo: PR
Philip Serlin photo: PR
Ashot Ashkelon credit: Ministry of Defense Up 250%, Ashot Ashkelon wins another Defense Ministry order

The Israeli defense company's share price has risen 250% in the past three years since FIMI Opportunity Funds acquired control.

Liad Agmon credit: Eyal Izhar Liad Agmon steps down from Insight Partners to found startup

Serial entrepreneur Agmon has served as a partner at Insight Partners Israel alongside Daniel Aronovitz who set up the Israel office.

Shekels credit: Shutterstock Vladerina32 Shekel slide resumes amid escalating tariff war

The Bank of Israel is not expected to intervene in the forex market despite the sharp depreciation of the shekel.

Nir Zuk credit: Inbal Marmari Palo Alto Networks mulls buying AI security co for $700m

Sources inform "Globes" that on Palo Alto's radar is Protect AI.

President Donald Trump hosts Prime Minister Benjamin Netanyahu credit: Reuters Kevin Mohatt Israeli officials confident on US tariff concessions

Senior Israeli figures believe that concessions could be tied to progress on strategic regional political issues that are important to President Trump.

Phoenix Investment House CEO Avner Hadad  credit: Tommy Harpaz "The market has priced in all the bad things"

Phoenix Investment House CEO Avner Hadad says US markets could continue to fall, but that we are close to interesting territory for patient investors.

Tel Aviv credit: Shutterstock Tel Aviv slips in World's Wealthiest Cities ranking

Tel Aviv's position as one of the world's wealthiest cities took a big knock over the past year as it slipped from 42nd to 48th in investment advisors Henley & Co.'s "World's Wealthiest Cities" Top 50 ranking.

Leviathan platform  credit: Albatross C'ttee seen recommending no cut in gas exports

The Dayan committee on the future of the gas sector estimates that Israel's natural gas reserves will run out in 2045.

Accountant General Yali Rothenberg credit: Rafi Kutz Israel's fiscal deficit continues to narrow

The deficit narrowed in the twelve months to the end of March 2025, for the sixth consecutive month, Ministry of Finance accountant general Yali Rothenberg reported today.

Arkia credit: Arkia Arkia cuts Tel Aviv - New York April fares

Arkia has cut fares at the last minute, a time when prices usually soar even higher, according to the pricing method used in the industry.

Bank of Israel Governor Prof. Amir Yaron credit: Dani Shem Tov Knesset Spokesperson BoI Governor: US tariffs could push up inflation in Israel

Prof. Amir Yaron tells "Globes" that there is a risk that the new tariffs will cause inflation to rise in the US, with a knock-on effect for Israel.

US President Donald Trump and Prime Minister Benjamin Netanyahu April 7, 2025  credit: Avi Ohayon, Government Press Office Netanyahu fails to persuade Trump to remove tariff on Israel

Asked by reporters whether Israel would be exempted from his tariffs policy, US President Donald Trump replied, "Maybe not. Don’t forget we help Israel a lot."

FBI to investigate Nakash Group Israel CEO

The complaint against Avi Hormaro was filed with the FBI offices in Miami, Florida, where many of the group's companies are incorporated, "Globes" has learned.

Bank of Israel credit: Shutterstock Israel's forex reserves fell in March

Israel’s foreign exchange reserves at the end of March 2025 fell to $218.821 billion, a decrease of $1.433 billion from their level at the end of February, the Bank of Israel reports.

Bank of Israel Governor Prof. Amir Yaron credit: GPO BoI keeps rate unchanged, cuts growth forecast

The Bank of Israel is concerned about inflation, the escalation of the war in Gaza, which has raised Israel's risk premium, and the turmoil on global markets set off by the trade war.

Eilat Ramon Airport Credit: Sivan Farag Eilat Municipal Spokesperson Russian airline to kick-start int'l flights from Eilat's Ramon airport

Russian airline Red Wings is to launch direct flights between Eilat's Ramon airport and Moscow and Sochi in Russia starting June 12.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018